282 related articles for article (PubMed ID: 36289617)
1. All Roads Lead to Cathepsins: The Role of Cathepsins in Non-Alcoholic Steatohepatitis-Induced Hepatocellular Carcinoma.
van Mourik H; Li M; Baumgartner S; Theys J; Shiri-Sverdlov R
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289617
[TBL] [Abstract][Full Text] [Related]
2. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; Ji P; French B; Tillman B; French SW
Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
[TBL] [Abstract][Full Text] [Related]
3. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.
Cholankeril G; Patel R; Khurana S; Satapathy SK
World J Hepatol; 2017 Apr; 9(11):533-543. PubMed ID: 28469809
[TBL] [Abstract][Full Text] [Related]
5. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
Hashimoto E; Tokushige K
Hepatol Res; 2012 Jan; 42(1):1-14. PubMed ID: 21917086
[TBL] [Abstract][Full Text] [Related]
7. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
[TBL] [Abstract][Full Text] [Related]
8. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
[TBL] [Abstract][Full Text] [Related]
9. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.
Takakura K; Oikawa T; Nakano M; Saeki C; Torisu Y; Kajihara M; Saruta M
Front Oncol; 2019; 9():762. PubMed ID: 31456946
[TBL] [Abstract][Full Text] [Related]
10. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
11. Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis.
Lamm R; Altshuler PJ; Patel K; Shaheen O; Amante AP; Civan J; Maley W; Frank A; Ramirez C; Glorioso J; Shah A; Dang H; Bodzin AS
Transpl Int; 2022; 35():10175. PubMed ID: 35865863
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
14. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.
Eguchi Y; Wong G; Lee IH; Akhtar O; Lopes R; Sumida Y
Hepatol Res; 2021 Jan; 51(1):19-30. PubMed ID: 33091191
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
17. Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma.
Hester CA; Rich NE; Singal AG; Yopp AC
J Natl Compr Canc Netw; 2019 Apr; 17(4):322-329. PubMed ID: 30959469
[TBL] [Abstract][Full Text] [Related]
18. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights.
Qin J; Higashi T; Nakagawa S; Fujiwara N; Yamashita YI; Beppu T; Baba H; Kobayashi M; Kumada H; Gunasekaran G; Schiano TD; Thung SN; Fiel MI; Hoshida Y; Ward SC
Am J Surg Pathol; 2020 Oct; 44(10):1406-1412. PubMed ID: 32618599
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Holzner ML; Florman S; Schwartz ME; Tabrizian P
HPB (Oxford); 2022 Apr; 24(4):470-477. PubMed ID: 34544629
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.
Gutiérrez-Cuevas J; Lucano-Landeros S; López-Cifuentes D; Santos A; Armendariz-Borunda J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
